

28 July 2025

BSE Limited
PJ Towers, 25th Floor,
Dalal Street
Mumbai 400001.
Scrip Code: 532175

National Stock Exchange of India Ltd
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E)
Mumbai-400 051.
Scrip Code: CYIENT

Dear Sir/ Madam,

Sub: Newspaper Advertisement

Ref: Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference to the captioned subject, please find enclosed the copy of the newspaper advertisement published in Business Standard all editions (English) and Mana Telangana (Telugu) on 26 July 2025 in connection with the Financials results for the quarter ended 30 June 2025, declared by Board of Directors on 24 July 2025.

This is for your information and records.

Thanking you
For Cyient Limited

Ravi Kumar Nukala
Dy. Company Secretary

Cyient Ltd. 4th Floor, A Wing, 11 Software
Units Layout, Madhapur
Hyderabad -500 081
India

CIN: L72200TG1991PLC013134
www.cyient.com
Company.secretary@cyient.com
T +91 40 6764 1000
F +91 40 2311 0352

Cipla Limited

CIN: L24239MH1935PLC002380

Regd. Office: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013.

Tel. No.: (022) 4191 6000 • Fax No.: (022) 4191 6120 • E-mail: cosecretary@cipla.com • Website: www.cipla.com

UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

FOR THE QUARTER ENDED 30TH JUNE, 2025

In compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the Board of Directors of the Cipla Limited ("Company") at its meeting held on Friday, 25th July, 2025 approved the unaudited financial results (standalone and consolidated) for the quarter ended 30th June, 2025 ("results").

The results, along with the limited review report (standalone and consolidated) by M/s. Walker ChandioK & Co LLP, Statutory Auditor of the Company are available on the website of the Company at www.cipla.com/investors/quarterly-results, and on websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively.

In compliance with Regulation 47 of the SEBI Listing Regulations, we hereby notify that the same can also be accessed by scanning the following Quick response (QR) code:

For CIPLA LIMITED

Sd/-

Rajendra Chopra

Company Secretary

Date: 25th July, 2025

Place: Mumbai

CYIENT

CIN: L72200TG1991PLC013134

Regd. Office: 4th Floor, 'A' Wing, Plot No. 11, Software Units Layout, Infocity, Madhapur, Hyderabad – 500 081, India

Ph: 040 - 67641322, Email: company.secretary@cyient.com, Website: www.cyient.com

Statement of Unaudited Consolidated and Standalone Financial Results for the Quarter Ended June 30, 2025

(₹ in Millions)

Sl. No.	Particulars	Consolidated Results			Standalone Results		
		Quarter Ended	Quarter Ended	Year Ended	Quarter Ended	Quarter Ended	Year Ended
		30-Jun-25	30-Jun-24	31-Mar-25	30-Jun-25	30-Jun-24	31-Mar-25
		Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
1	Revenue from contracts with customers	17,118	16,757	73,604	5,485	5,696	24,136
2	Net Profit for the period (before Tax and/or Exceptional items)	2,136	1,946	8,750	1,610	1,077	5,443
3	Net Profit for the period before tax (after Exceptional items)	2,136	1,946	8,750	1,610	1,077	13,274
4	Net Profit for the period after tax (after Exceptional items)	1,574	1,476	6,483	1,187	798	11,246
	Attributable to:						
	Shareholders of the Company	1,538	1,439	6,157	1,187	798	11,246
	Non-controlling interests	36	37	326	-	-	-
5	Total Comprehensive Income for the period	2,303	1,465	6,782	1,088	822	11,280
	Attributable to:						
	Shareholders of the Company	2,267	1,427	6,612	1,088	822	11,280
	Non-controlling interests	36	38	170	-	-	-
6	Earnings Per Share [Face Value of ₹ 5 per share]						
	(a) Basic (in ₹)	13.95	13.09	55.95	10.77	7.26	102.20
	(b) Diluted (in ₹)	13.86	12.98	55.51	10.70	7.20	101.39

*EPS for the quarters are not annualised.

NOTES :

1. The unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on July 23, 2025 and July 24, 2025, respectively. The Statutory Auditors have expressed an unmodified opinion on the unaudited consolidated and standalone financial results.

2. The above financial results are an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results is available on the Stock Exchange websites: www.bseindia.com and www.nseindia.com, and also on the Company's website: www.cyient.com. The same can also be accessed by scanning the QR code provided below.

For CYIENT LIMITED

Sd/-

KRISHNA BODANAPU

Executive Vice Chairman and Managing Director

Place : Hyderabad

Date : July 24, 2025

LAURUS Labs

Chemistry for Better Living

Laurus Labs Limited

(CIN: L24239AP2005PLC047518)

Regd.Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh - 531021, India

Corp.Office: 2nd Floor, SDE Serene Chambers, Road No.7, Banjara Hills, Hyderabad - 500034, Telangana, India

Tel: +91 040 3980 4333 | Fax: +91 040 3980 4320 | E-mail: secretarial@lauruslabs.com | Website: www.lauruslabs.com

Extract of Consolidated Unaudited Financial results for the quarter ended June 30, 2025 which are prepared in compliance with Indian Accounting Standards.

(₹ in Crores)

SL. No.	Particulars	Quarter ended		Year ended	
		30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total revenue from operations	1,569.57	1,720.30	1,194.91	5,553.96
2	Net Profit for the period (before tax, Exceptional and/or Extraordinary items)	224.22	312.34	18.46	484.29
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	224.22	312.34	18.46	484.29
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	161.68	232.77	12.68	358.34
5	Total Comprehensive Income for the period	160.97	230.70	12.99	354.69
6	Net Profit for the period after tax (after Exceptional and/or Extraordinary items) attributable to:				
	i) Equity holders of the Company	163.02	233.67	12.51	358.32
	ii) Non-controlling interests	(1.34)	(0.90)	0.17	0.02
7	Total Comprehensive Income for the period attributable to:				
	i) Equity holders of the Company	162.31	231.60	12.82	354.67
	ii) Non-controlling interests	(1.34)	(0.90)	0.17	0.02
8	Equity Share Capital	107.96	107.85	107.83	107.85
9	Reserves (excluding Revaluation Reserve) and Non-controlling interests as shown in the Audited Balance Sheet				4,364.71
10	Earnings Per Share (of ₹2/- each)				
	1. Basic : ₹*	3.02	4.34	0.23	6.65
	2. Diluted : ₹*	3.02	4.33	0.23	6.64

* Not annualised for quarter ended.

Notes :

1. Additional information on Standalone Unaudited financial results for the quarter ended June 30, 2025

(₹ in Crores)

SL. No.	Particulars	Quarter ended		Year ended	
		30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total revenue from operations	1,432.75	1,650.01	1,116.93	5,216.98
2	Profit before tax	211.44	330.20	38.80	503.81
3	Profit after tax	157.94	251.90	28.78	380.39
4	Total Comprehensive Income for the period	157.75	250.29	29.06	379.63

2. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the Stock Exchanges and the Company namely www.bseindia.com, www.nseindia.com and www.lauruslabs.com. The same can be accessed by scanning the QR code provided below.

3. The above financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on July 25, 2025.

By order of the Board

For Laurus Labs Limited

Sd/-

Dr. Satyanarayana Chava

Whole Time Director & Chief Executive Officer

Place: Hyderabad

Date : July 25, 2025

SOLARA

Active Pharma Sciences

SOLARA ACTIVE PHARMA SCIENCES LIMITED

CIN: L24230MH2017PLC291636

Regd. Office: 9th Floor, "Cyber One", Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703

Tel: +91-22-2789 2924

Corporate Office: TICEL BIO PARK, 6th floor Module No. 601, 602, 603, Phase II - CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 | Fax: +91 44 47406190 | E-mail: investors@solara.co.in, www.solara.co.in

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(Rs. in Crores except per share data)

Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Previous Financial Year ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		UNAUDITED	(Refer Note 5)	UNAUDITED	AUDITED
	Continuing operations:				
1	Total income from operations	319.15	273.01	363.49	1,283.76
2	Net Profit for the period before tax (before exceptional items)	10.52	(2.10)	(13.46)	0.54
3	Net Profit for the period before tax (after exceptional items)	10.52	(2.10)	(13.46)	0.54
4	Net Profit for the period after tax	10.52	(2.10)	(13.46)	0.54
5	Other Comprehensive Income for the period	(0.01)	(0.62)	(0.01)	0.98
6	Total Comprehensive Income for the period (4 + 5)	10.51	(2.72)	(13.47)	1.52
7	Equity Share Capital	44.34	40.25	40.21	40.25
8	Other Equity				1,053.99
9	Earnings Per Share (of Rs. 10/- each) (for continuing operations) -				
	Basic (Rs.)	2.46	(0.93)	(3.50)	0.14
	Diluted (Rs.)	2.46	(0.93)	(3.50)	0.14

Notes:

1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the National Stock Exchange of India Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and at the Company's website (www.solara.co.in)

2 The above consolidated financial results of Solara Active Pharma Sciences Limited ("the Parent" or the Company" and its subsidiaries (together referred to as "the group") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on July 25, 2025. The results for the quarter ended June 30, 2025 has been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company. The statutory auditors of the Company have expressed an unmodified conclusion in respect of limited review for the quarter ended June 30, 2025.

3 The Parent, vide its letter of offer dated May 09, 2024 offered upto 1,19,98,755 partly paid equity shares of face value of Rs.10/- each at a price of Rs. 375 per Equity share (including Share premium of Rs. 365 per Equity share) for an amount aggregating Rs. 449.95 crores to the existing share holders of the Parent on right basis in the ratio of One Equity share for every three Equity shares held by the Equity shareholders on the record date i.e May 15, 2024. Rights issue has been done in accordance with Section 62(1)(a) of the Companies Act and other applicable laws. The Parent has allotted 1,19,98,755 Nos. of partly paid up equity shares on June 19, 2024.

On March 26, 2025, the Company, approved the Rights Issue First Call of Rs.131.25 per Rights Share (Rs. 3.50 face value and Rs.127.75 Share premium) for 1,19,98,755 partly paid Rights Shares, as per the Letter of Offer dated May 09, 2024. The First Call payment window was open from April 16, 2025 to April 30, 2025. The Rights Issue Committee on May 06, 2025, took note of receipt of First call money amounting Rs.149.49 Crores and approved conversion of 1,13,89,767 partly paid shares of Rs. 3.5 per share to partly paid of Rs. 7 per share.

Out of net proceeds from First Call money, Rs. 115.00 crores is used against repayment of borrowings, Rs.23.27 crores towards general corporate purposes in line with terms of utilization mentioned in letter of offer.

4 The Board of Directors of the Parent at its meeting held on January 24, 2025 had discussed a proposal to explore 'demerger of the CRAMS and Polymers business into an independent listed entity' and granted in-principle approval for the same. Pursuant to this, the Parent incorporated a wholly owned subsidiary, Synthix Global Pharma Solutions Limited, on April 29, 2025.

5 The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and year to date figures up to third quarter of the financial year then ended as disclosed in the financial results for the year ended March 31, 2025.

For and on behalf of board

Sd/-

Sandeep Shashikantha Rao

MD & CEO

Place : Bengaluru

Date : July 25, 2025

TATA

Extracts of Statement of Consolidated Financial Results

for the quarter ended 30 June, 2025

(₹ in crore)

Particulars	Quarter ended 30 June, 2025	Quarter ended 31 March, 2025	Quarter ended 30 June, 2024	Year ended 31 March, 2025
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Not annualised			Annualised
1. Revenue from continuing operations	3,719	3,509	3,789	14,887
2. Profit/(loss) from continuing operations before exceptional items, share of profit/(loss) of joint ventures and associate and tax	318	(61)	215	492
3. Profit/(loss) from continuing operations after exceptional items, before share of profit/(loss) of joint ventures and associate and tax	318	(116)	215	367
4. Profit/(loss) from continuing operations before tax	360	(92)	269	521
5. Profit/(loss) from continuing operations after tax	316	(67)	175	354
6. Profit/(loss) from discontinued operations after tax	-	18	15	33
7. Profit/(loss) for the period (5 + 6)	316	(49)	190	387
8. Total comprehensive income for the period	1,037	(79)	(178)	(114)
9. Paid-up equity share capital (Face value: ₹ 10 per share)	255	255	255	255
10. Other equity and Non-controlling interests				22,246
11. Securities premium account	1,259	1,259	1,259	1,259
12. Net worth	23,215	22,501	22,514	22,501
13. Outstanding debt	7,126	7,072	6,376	7,072
14. Earnings per share				
- Basic and Diluted (for continuing operations) in ₹	9.89	(2.90)	5.30	7.93
- Basic and Diluted (for discontinued operations) in ₹	-	0.71	0.59	1.30
- Basic and Diluted (for continuing and discontinued operations) in ₹	9.89	(2.19)	5.89	9.23
15. Debt equity ratio (no. of times)	0.31	0.31	0.28	0.31
16. Debt service coverage ratio (no. of times)	3.88	2.84	3.35	2.71
17. Interest service coverage ratio (no. of times)	4.41	2.39	4.32	3.47

TATA

Extracts of Statement of Standalone Audited Financial Results

for the quarter ended 30 June, 2025

(₹ in crore)

Particulars	Quarter ended 30 June, 2025	Quarter ended 31 March, 2025	Quarter ended 30 June, 2024	Year ended 31 March, 2025
	Not annualised			Annualised
1. Revenue from continuing operations	1,169	1,219	1,047	4,441
2. Profit from continuing operations before tax	332	102	322	624
3. Profit from continuing operations after tax	307	97	256	524
4. Profit from discontinued operations after tax	-	18	15	33
5. Profit for the period (3 + 4)	307	115	271	557
6. Total comprehensive income for the period	1,060	(18)	(120)	(149)
7. Paid-up equity share capital (Face value: ₹ 10 per share)	255	255	255	255
8. Other equity				17,939
9. Securities premium account	1,258	1,258	1,258	1,258
10. Net worth	18,974	18,194	18,223	18,194
11. Outstanding debt	1,979	2,261	574	2,261
12. Earnings per share				
- Basic and Diluted (for continuing operations) in ₹	12.05	3.80	10.05	20.57
- Basic and Diluted (for discontinued operations) in ₹	-	0.71	0.59	1.30
- Basic and Diluted (for continuing and discontinued operations) in ₹	12.05	4.51	10.64	21.87
13. Debt equity ratio (no. of times)	0.10	0.12	0.03	0.12
14. Debt service coverage ratio (no. of times)	19.29	5.23	27.20	13.86
15. Interest service coverage ratio (no. of times)	5.40	4.69	18.08	5.68

For and on behalf of the Board of

TATA CHEMICALS LIMITED

R. Mukundan

Managing Director and CEO

Place : Mumbai

Date : 25 July, 2025



దుకు చెందిన ఆరుగురు సభ్యులు గురువారం తమ పద
వీకాలం పూర్తయిన తర్వాత పదవీ విరమణ చేశారు.